OPK - OPKO Health, Inc.
Pre-Market:
Chart Events
Williams %R
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.4100 |
| Open | 1.4400 |
| Bid | 1.4000 x 2900 |
| Ask | 1.4200 x 3000 |
| Day's Range | 1.3700 - 1.4500 |
| 52 Week Range | 1.0000 - 3.1100 |
| Volume | |
| Avg. Volume | 3,102,350 |
| Market Cap | 1.074B |
| Beta (5Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3900 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.85 |
Fair Value
Related Research
Simply Wall St.Gary Nabel Spends US$541k On OPKO Health Stock \
Those following along with OPKO Health, Inc. ( NASDAQ:OPK ) will no doubt be intrigued by the recent purchase of shares...
ZacksOPKO Health (OPK) Q1 Earnings and Revenues Top Estimates
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.
- Thomson Reuters StreetEvents
Q1 2023 OPKO Health Inc Earnings Call
Q1 2023 OPKO Health Inc Earnings Call
Motley FoolOpko Health (OPK) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool. Opko Health (NASDAQ: OPK)Q1 2023 Earnings CallMay 03, 2023, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to the OPKO Health first quarter 2023 financial results conference call.
ZacksOPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates
OPKO Health (OPK) delivered earnings and revenue surprises of 71.43% and 26.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireOPKO Health Reports First Quarter 2023 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights include the following: OPKO Health’s ModeX Therapeutics, Inc. (ModeX) entered into an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201 for Epstein-Barr virus. Under the terms of the agreement, OPKO received a
- GlobeNewswire
OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023
MIAMI, April 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financial markets on Wednesday, May 3, 2023. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 3rd beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages partici
- Simply Wall St.
With 46% ownership, insiders at OPKO Health, Inc. (NASDAQ:OPK) are pretty optimistic and have been buying recently
Key Insights Insiders appear to have a vested interest in OPKO Health's growth, as seen by their sizeable ownership 50...
- Simply Wall St.
The Chairman & CEO of OPKO Health, Inc. (NASDAQ:OPK), Phillip Frost, Just Bought A Few More Shares
OPKO Health, Inc. ( NASDAQ:OPK ) shareholders (or potential shareholders) will be happy to see that the Chairman & CEO...
ZacksOPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up
OPKO Health's (OPK) entry into a worldwide license and collaboration agreement with Merck is expected to aid in developing a vaccine against EBV.
Insider Monkey10 Penny Stocks with Insider Buying
In this piece, we will take a look at ten penny stocks with insider buying. For more penny stocks, head on over to 5 Penny Stocks with Insider Buying. With the first quarter of 2023 coming to an end, the stock market continues to be in a topsy-turvy environment. 2023 was off to a strong […]
- GlobeNewswire
OPKO Health to Hold Virtual R&D Day on March 20, 2023
MIAMI, March 09, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time. The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX Therapeutics multispecific technology platforms and applications in oncology and infectious diseases. Management will also review the MDX-2201 technology underlying the recently announced license and collaboration agreem
Motley FoolWhy OPKO Health Shares Jumped on Wednesday
Shares of drug and diagnostics company OPKO Health (NASDAQ: OPK) closed 8% higher Wednesday following news of a collaboration agreement with pharmaceutical giant Merck (NYSE: MRK). While down from an intraday rally of more than 24%, the remaining gain still offers a glimmer of hope to shareholders who've watched their OPKO stake crumble since early 2021. The target is Epstein-Barr, a virus linked to mononucleosis that's vexed the healthcare industry since it was first identified in 1964.
BenzingaOPKO Health's Cancer & Infectious Disease Focused Subsidiary Inks Vaccine Development Pact With Merck
ModeX Therapeutics Inc, a unit of OPKO Health Inc (NASDAQ: OPK), entered into an exclusive worldwide license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop MDX-2201, ModeX's preclinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV). EBV is the leading cause of infectious mononucleosis and is also associated with some specific types of cancer. "Targeting four proteins used by EBV to infect cells, this vaccine candidate embodies the novel multitargeting
ReutersOpko Health shares rise on Merck deal for experimental Epstein-Barr vaccine
Shares of Opko rose as much as 24%, before paring gains to trade 9.4% higher at $1.16. Merck will take over the clinical and regulatory activities related to the vaccine, as well its commercialization once the drugmaker files a joint application with Opko unit ModeX Therapeutics to test it in humans, the company said. Opko will receive an upfront payment of $50 million and is eligible for milestone payments of up to $872.5 million, plus royalties, on global sales.
- Reuters
Merck, Opko Health sign deal for experimental Epstein-Barr virus vaccine
Opko Health Inc said on Wednesday it signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine. Merck will take over the clinical and regulatory activities related to the vaccine, as well its commercialization once the drugmaker files a joint application with Opko unit ModeX Therapeutics to test it in humans, the company said. Opko will receive an upfront payment of $50 million and is eligible for milestone payments of up to $872.5 million, plus royalties on global sales.
- GlobeNewswire
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
MDX-2201 leverages ModeX’s innovative biologics platform to target multiple Epstein-Barr virus (EBV) proteinsEBV is the leading cause of infectious mononucleosis and is also associated with some specific types of cancer MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD outside the United States and Canada,
- Simply Wall St.
OPKO Health Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
OPKO Health ( NASDAQ:OPK ) Full Year 2022 Results Key Financial Results Revenue: US$1.00b (down 43% from FY 2021). Net...
Insider MonkeyOPKO Health, Inc. (NASDAQ:OPK) Q4 2022 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Good day, and welcome to the OPKO Health Fourth Quarter 2022 Financial Results Conference Call. . I would now like to turn the conference over to Yvonne Briggs with LHA. Please go ahead. Yvonne Briggs: Thank you, operator, and good afternoon. This […]
ZacksOPKO Health (OPK) Q4 Earnings Match Estimates, Revenues Top
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
- Thomson Reuters StreetEvents
Q4 2022 OPKO Health Inc Earnings Call
Q4 2022 OPKO Health Inc Earnings Call
- Motley Fool
Opko Health (OPK) Q4 2022 Earnings Call Transcript
Image source: The Motley Fool. Opko Health (NASDAQ: OPK)Q4 2022 Earnings CallFeb 23, 2023, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the OPKO Health fourth quarter 2022 financial results conference call.
- GlobeNewswire
OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2022. Business highlights include the following: Sales are underway by Pfizer for NGENLA® (somatrogon) in 15 countries including Japan, Germany and the United Kingdom; Pfizer expects to launch in all priority ex-U.S. markets by year-end and is continuing to work with the FDA to obta
ZacksHere's Why You Should Retain OPKO Health (OPK) Stock for Now
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
- GlobeNewswire
OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 23rd beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encou